Table 2. Mobilization of adult stem cells-clinical trials mentioned in the text.

Trial	Year/reference	Study design	Patients (number)	Patients (diagnosis)	Drug type	Drug dose/application	Follow up (months)	Follow up (method)	Functional outcome (LVEF)
EPOC-AMI	2010. (18)	r, ol, be, c	35	STEMI (PCI)	EPO (low dose)	One dose of 6,000 IU during PCI	6	SPECT	Significantly improved by 6.5% (EPO group baseline vs. 6 months follow-up, P=0.003), no significant improvement in controls
Bergmann et al.	2011. (19)	r, db, pc	28	HF (PCI)	EPO (low dose)	35 IU/kg body weight (weekly for 6 months)	6	echo, MRI	Significantly improved by 4.9% (echo, P=0.019) and 5.0% (MRI, P=0.042) (EPO group vs. placebo)
STEM-AMI	2010. (20)	p, r, sb, pc	60	STEMI (PCI) (LVEF <45%)	G-CSF	G-CSF 5 µg/kg subcutaneously (daily for 5 days)	6	MRI	No significant improvement (G-CSF group vs. placebo)
MAGIC Cell-3-DES	2012. (21)	r, c	117	MI (PCI)	G-CSF + subsequent injection of PBMCs	G-CSF 10 µg/kg subcutaneously (daily for 3 days) + PBMC injection (im)	24	MRI	No significant improvement (G-CSF/PBMC group vs. control)

Abbreviations: LVEF, left ventricular ejection fraction; r, randomized; ol, open label; be, blinded endpoints; sb, single blinded; db, double blinded; c, controlled; pc, placebo-controlled; STEMI, ST-segment elevation acute myocardial infarction; MI, myocardial infarction; HF, heart failure; PCI, percutaneous coronary intervention; EPO, erythropoietin; G-CSF, granulocyte colony stimulating factor; PBSCs, peripheral blood stem cells; im, intramyocardial; echo, echocardiography; MRI, magnetic resonance imaging; SPECT, single-photon emission computed tomography.